Condition
MAP2K1 Gene Mutation
Total Trials
3
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Recruiting1
Active Not Recruiting1
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT05983159Phase 2Recruiting
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
NCT03087071Phase 2Active Not Recruiting
Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
NCT04488003Phase 2Terminated
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Showing all 3 trials